Partners Capital Investment Group LLP Buys 8,774 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Partners Capital Investment Group LLP increased its stake in Thermo Fisher Scientific Inc. by 87.9%, acquiring an additional 8,774 shares during the first quarter, bringing its total holdings to 18,753 shares worth approximately $9.33 million.
• Recent insider activity included CEO Marc N. Casper selling 8,000 shares for about $3.63 million, and EVP Gianluca Pettiti selling 400 shares valued at nearly $192,000, representing notable decreases in their ownership percentages.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, with an annualized yield of 0.3%, which will be paid to shareholders on October 15th.

Partners Capital Investment Group LLP grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 87.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,753 shares of the medical research company's stock after acquiring an additional 8,774 shares during the quarter. Partners Capital Investment Group LLP's holdings in Thermo Fisher Scientific were worth $9,331,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of TMO. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the last quarter. Port Capital LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.6% in the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after acquiring an additional 22 shares during the last quarter. Clark Capital Management Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after purchasing an additional 23 shares in the last quarter. Monograph Wealth Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after purchasing an additional 23 shares during the last quarter. Finally, Intergy Private Wealth LLC lifted its stake in Thermo Fisher Scientific by 5.8% in the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after purchasing an additional 23 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 8,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,340,824.30. The trade was a 6.49% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 18,400 shares of company stock valued at $8,345,792. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 0.7%

NYSE:TMO opened at $494.8160 on Thursday. The firm has a fifty day simple moving average of $439.69 and a two-hundred day simple moving average of $458.78. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The stock has a market capitalization of $186.85 billion, a price-to-earnings ratio of 28.62, a PEG ratio of 2.66 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 EPS. The business's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research note on Friday, July 11th. Argus dropped their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Finally, Royal Bank Of Canada decreased their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.